{
  "main_header": {
    "sid": 456242,
    "name": "RPG LifeScience.",
    "stock_name": "RPG LifeScience.",
    "full_name": "RPG Life Sciences Ltd",
    "name_url": "stocks-analysis/rpg-lifescience",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "2,085.35",
    "chg": 106.35,
    "chgp": "5.37%",
    "dir": 1,
    "prev_price": "1,979.00",
    "mcapval": "3,448.96 Cr",
    "mcap": "Small Cap",
    "scripcode": 532983,
    "symbol": "RPGLIFE",
    "ind_name": "Pharmaceuticals & Drugs",
    "ind_code": 4,
    "isin": "INE105J01010",
    "curr_date": "Apr 11, 12:53 PM",
    "curr_time": "00:12 AM",
    "bse_nse_vol": "7.9 k",
    "exc_status": "Active",
    "traded_date": "Apr 11, 2025",
    "traded_date_str": "2025 04 11",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://sandbox-www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/rpg-lifescience-456242-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "RPG Life Sciences Adjusts Valuation Grade Amid Strong Market Performance and Competitive Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-valuation-grade-downgraded-from-very-expensive-to-expensive-10-1669848",
        "imagepath": "",
        "date": "2025-04-02 08:01:00",
        "description": "RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing within the pharmaceuticals and drugs sector. The company, categorized as a small-cap entity, showcases a price-to-earnings (PE) ratio of 43.00 and a price-to-book value of 9.83. Its enterprise value to EBITDA stands at 23.27, while the enterprise value to EBIT is recorded at 26.83. Additionally, RPG Life Sciences has a PEG ratio of 18.60 and a dividend yield of 0.71%. \n\nIn terms of performance, the company has demonstrated strong returns over various periods, with a notable 46.05% increase over the past year, significantly outperforming the Sensex, which recorded a 2.72% return in the same timeframe. Over the last five years, RPG Life Sciences has achieved an impressive 1206.87% return, compared to the Sensex's 168.97%.\n\nWhen compared to its peers, RPG Life Sciences maintains a competitive position, with several..."
      },
      {
        "title": "RPG Life Sciences Adjusts Valuation Grade Amid Strong Financial Metrics and Market Position",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-valuation-grade-changes-from-expensive-to-very-expensive-amid-stock-surge-1463281",
        "imagepath": "",
        "date": "2025-03-19 08:00:19",
        "description": "RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs industry. The company's price-to-earnings ratio stands at 42.23, while its price-to-book value is noted at 9.65. Additionally, RPG Life Sciences shows a robust return on capital employed (ROCE) of 49.08% and a return on equity (ROE) of 22.86%, indicating strong operational efficiency and profitability.\n\nIn comparison to its peers, RPG Life Sciences maintains a competitive edge with its valuation metrics. For instance, while Hikal and Unichem Labs are categorized differently, RPG Life Sciences' EV to EBITDA ratio of 22.83 and PEG ratio of 18.26 position it favorably within the sector. Notably, the company has demonstrated significant stock performance over various periods, with a remarkable 267.85% return over three years, outpacing the Sensex's 30.14% return in the same timeframe..."
      },
      {
        "title": "RPG Life Sciences Shows Mixed Technical Trends Amid Strong Long-Term Growth Potential",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-strong-performance-3-1501131",
        "imagepath": "",
        "date": "2025-03-18 08:01:37",
        "description": "RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 2109.70, showing a notable increase from the previous close of 2064.00. Over the past week, RPG Life Sciences has demonstrated a stock return of 1.36%, significantly outperforming the Sensex, which returned just 0.07% in the same period.\n\nThe company's performance metrics reveal a mixed technical landscape. While the weekly MACD and KST indicators suggest a mildly bearish outlook, the monthly Bollinger Bands indicate a bullish trend. Additionally, the daily moving averages lean towards a mildly bullish sentiment, suggesting some positive momentum in the short term.\n\nRPG Life Sciences has shown impressive long-term returns, with a remarkable 1597.26% increase over the past decade, compared to the Sensex's 158.10% ..."
      },
      {
        "title": "RPG Life Sciences Faces Mixed Technical Trends Amid Notable Stock Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-technical-trend-shifts-from-mildly-bullish-to-sideways-amid-price-decline-2-1312362",
        "imagepath": "",
        "date": "2025-03-11 08:02:00",
        "description": "RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock, which closed at 2081.30, has seen fluctuations with a 52-week high of 2,976.70 and a low of 1,363.90. Today's trading session recorded a high of 2176.35 and a low of 2060.00, indicating some volatility.\n\nThe technical summary reveals a mixed picture. The MACD indicators suggest a mildly bearish stance on both weekly and monthly charts, while the Bollinger Bands show a bearish trend weekly but a mildly bullish outlook monthly. Moving averages indicate a mildly bullish trend on a daily basis, contrasting with the overall bearish signals from the KST and Dow Theory metrics.\n\nIn terms of performance, RPG Life Sciences has shown notable returns over various periods. Over the past year, the stock has gained 38.46%, significantly outperformi..."
      },
      {
        "title": "RPG Life Sciences Adjusts Valuation Grade Amid Strong Market Performance and Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-valuation-grade-downgraded-from-very-expensive-to-expensive-9-1516422",
        "imagepath": "",
        "date": "2025-03-11 08:00:11",
        "description": "RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings ratio stands at 39.69, while its price-to-book value is noted at 9.07. Other key metrics include an EV to EBIT ratio of 24.69 and an EV to EBITDA ratio of 21.41, indicating a robust operational performance.\n\nThe company has demonstrated strong returns over the long term, with a remarkable 294.48% increase over three years and an impressive 905.70% rise over five years. In contrast, the Sensex has shown a 33.63% increase over the same three-year period and 107.98% over five years, highlighting RPG Life Sciences' superior performance relative to the broader market.\n\nIn terms of profitability, the company boasts a return on capital employed (ROCE) of 49.08% and a return on equity (ROE) of 22.86%, underscoring its effective management and opera..."
      },
      {
        "title": "RPG Life Sciences Shows Mixed Technical Trends Amid Strong Long-Term Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-technical-trend-shifts-from-sideways-to-mildly-bullish-amid-strong-performance-1228894",
        "imagepath": "",
        "date": "2025-03-07 08:01:46",
        "description": "RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 2,173.80, showing a notable increase from the previous close of 2,118.95. Over the past year, RPG Life Sciences has demonstrated a strong performance, with a return of 43.42%, significantly outpacing the Sensex, which recorded a mere 0.34% return in the same period.\n\nThe technical summary indicates a mixed outlook, with various indicators reflecting different trends. The MACD shows a mildly bearish stance on a weekly basis but is bullish on a monthly scale. Similarly, the Bollinger Bands and KST present a mildly bearish trend weekly, while the monthly perspective appears more favorable. The daily moving averages suggest a mildly bullish sentiment, indicating some positive momentum in the short term.\n\nIn terms of ..."
      },
      {
        "title": "RPG Life Sciences Opens Strong with 5.17% Gain, Outpacing Sector Trends",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-stock-opens-5-17-higher-reaching-intraday-high-of-rs-2228-4-1215187",
        "imagepath": "",
        "date": "2025-03-06 09:40:17",
        "description": "RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has shown significant activity today, opening with a gain of 5.17%. The stock's performance has outpaced its sector by 1.38%, marking a notable trend as it has gained for three consecutive days, accumulating a total return of 7.23% during this period. \n\nToday, RPG Life Sciences reached an intraday high of Rs 2228.4, reflecting strong market engagement. In terms of moving averages, the stock is currently above its 5-day and 200-day averages, although it remains below the 20-day, 50-day, and 100-day averages. \n\nIn the broader market context, RPG Life Sciences has performed 1.62% better than the Sensex today, which saw a slight decline of 0.08%. However, over the past month, the stock has faced challenges, declining by 14.82%, compared to the Sensex's drop of 5.62%. \n\nTechnical indicators suggest a mixed outlook, with the MACD and B..."
      },
      {
        "title": "RPG Life Sciences Shows Strong Long-Term Returns Amid Mixed Technical Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-technical-trend-shifts-from-mildly-bearish-to-sideways-amid-stock-price-increase-1200338",
        "imagepath": "",
        "date": "2025-03-05 08:01:13",
        "description": "RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock, which closed at 2088.10, has shown a notable performance over various time frames, particularly in the long term. Over the past year, RPG Life Sciences has delivered a return of 36.64%, significantly outperforming the Sensex, which recorded a mere 1.19% return in the same period. \n\nIn the three-year and five-year spans, the company has demonstrated remarkable growth, with returns of 320.18% and 805.11%, respectively, compared to the Sensex's 34.34% and 90.03%. This long-term performance highlights the company's resilience and ability to navigate market challenges effectively.\n\nHowever, recent technical indicators present a mixed picture. The MACD and KST metrics indicate a mildly bearish sentiment on both weekly and monthly bases, whi..."
      },
      {
        "title": "RPG Life Sciences Adjusts Valuation Grade Amid Strong Operational Performance Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/rpg-life-sciences-valuation-grade-downgraded-from-very-expensive-to-expensive-1153888",
        "imagepath": "",
        "date": "2025-03-01 08:00:24",
        "description": "RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings ratio stands at 39.82, while its price-to-book value is noted at 9.10. Other key metrics include an EV to EBIT ratio of 24.77 and an EV to EBITDA ratio of 21.48, indicating a robust operational performance.\n\nThe company has demonstrated a strong return on capital employed (ROCE) of 49.08% and a return on equity (ROE) of 22.86%, showcasing effective management and profitability. Despite a recent decline in stock price, RPG Life Sciences has outperformed the Sensex over longer periods, with a remarkable 321.81% return over three years and a staggering 764.93% over five years.\n\nIn comparison to its peers, RPG Life Sciences maintains a competitive position, with its valuation metrics aligning closely with other companies in the sector. Notably,..."
      }
    ],
    "total": 97,
    "sid": "456242",
    "stock_news_url": "https://sandbox-www.marketsmojo.com/news/rpg-life-sciences-456242"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "08-Apr-2025",
      "details": "Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations 2015 we wish to inform you that on the recommendation of the Nomination and Remuneration Committee the Board of Directors on April 7 2025 has approved appointment of Ms Sheetal Gaba as Chief Human Resource Officer (CHRO) in capacity of a Senior Management Personnel of the Company w.e.f April 7 2025.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "25-Mar-2025",
      "details": "This is to inform you that pursuant to Code of Fair Disclosure Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading by Insiders of the Company and SEBI (Prohibition of Insiders Trading) Regulation 2015 the Trading window for dealing in securities of the company by Designated Persons and their immediate relatives shall remain Closed from Tuesday April 1 2025 until 48 hours after the declaration of audited financial results by the Company for the year ending on March 31 2025. The date of Board Meeting of the Company for consideration and declaration of audited financial results for the year ending on March 31 2025 will be intimated in due course",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.",
      "datetime": "21-Mar-2025",
      "details": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirement regulation 2015 and securities and exchange board of India (listing obligations and disclosure requirements) (Third Amendment) Regulations 2024 dated December 13 2024 we wish to inform you that the company has received an order from Assessment unit Income Tax Department and details are enclosed as per SEBI Circular no SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated July 13 2023 in Annexure Ato this disclosure",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "RPG Life Sciences Ltd has declared <strong>200%</strong> dividend, ex-date: 28 Jun 24",
          "dt": "2024-06-28",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

RPG Life Sciences Adjusts Valuation Grade Amid Strong Market Performance and Competitive Positioning

2025-04-02 08:01:00

RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing within the pharmaceuticals and drugs sector. The company, categorized as a small-cap entity, showcases a price-to-earnings (PE) ratio of 43.00 and a price-to-book value of 9.83. Its enterprise value to EBITDA stands at 23.27, while the enterprise value to EBIT is recorded at 26.83. Additionally, RPG Life Sciences has a PEG ratio of 18.60 and a dividend yield of 0.71%. In terms of performance, the company has demonstrated strong returns over various periods, with a notable 46.05% increase over the past year, significantly outperforming the Sensex, which recorded a 2.72% return in the same timeframe. Over the last five years, RPG Life Sciences has achieved an impressive 1206.87% return, compared to the Sensex's 168.97%. When compared to its peers, RPG Life Sciences maintains a competitive position, with several...

Read More

RPG Life Sciences Adjusts Valuation Grade Amid Strong Financial Metrics and Market Position

2025-03-19 08:00:19

RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs industry. The company's price-to-earnings ratio stands at 42.23, while its price-to-book value is noted at 9.65. Additionally, RPG Life Sciences shows a robust return on capital employed (ROCE) of 49.08% and a return on equity (ROE) of 22.86%, indicating strong operational efficiency and profitability. In comparison to its peers, RPG Life Sciences maintains a competitive edge with its valuation metrics. For instance, while Hikal and Unichem Labs are categorized differently, RPG Life Sciences' EV to EBITDA ratio of 22.83 and PEG ratio of 18.26 position it favorably within the sector. Notably, the company has demonstrated significant stock performance over various periods, with a remarkable 267.85% return over three years, outpacing the Sensex's 30.14% return in the same timeframe...

Read More

RPG Life Sciences Shows Mixed Technical Trends Amid Strong Long-Term Growth Potential

2025-03-18 08:01:37

RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 2109.70, showing a notable increase from the previous close of 2064.00. Over the past week, RPG Life Sciences has demonstrated a stock return of 1.36%, significantly outperforming the Sensex, which returned just 0.07% in the same period. The company's performance metrics reveal a mixed technical landscape. While the weekly MACD and KST indicators suggest a mildly bearish outlook, the monthly Bollinger Bands indicate a bullish trend. Additionally, the daily moving averages lean towards a mildly bullish sentiment, suggesting some positive momentum in the short term. RPG Life Sciences has shown impressive long-term returns, with a remarkable 1597.26% increase over the past decade, compared to the Sensex's 158.10% ...

Read More

RPG Life Sciences Faces Mixed Technical Trends Amid Notable Stock Performance

2025-03-11 08:02:00

RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock, which closed at 2081.30, has seen fluctuations with a 52-week high of 2,976.70 and a low of 1,363.90. Today's trading session recorded a high of 2176.35 and a low of 2060.00, indicating some volatility. The technical summary reveals a mixed picture. The MACD indicators suggest a mildly bearish stance on both weekly and monthly charts, while the Bollinger Bands show a bearish trend weekly but a mildly bullish outlook monthly. Moving averages indicate a mildly bullish trend on a daily basis, contrasting with the overall bearish signals from the KST and Dow Theory metrics. In terms of performance, RPG Life Sciences has shown notable returns over various periods. Over the past year, the stock has gained 38.46%, significantly outperformi...

Read More

RPG Life Sciences Adjusts Valuation Grade Amid Strong Market Performance and Metrics

2025-03-11 08:00:11

RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings ratio stands at 39.69, while its price-to-book value is noted at 9.07. Other key metrics include an EV to EBIT ratio of 24.69 and an EV to EBITDA ratio of 21.41, indicating a robust operational performance. The company has demonstrated strong returns over the long term, with a remarkable 294.48% increase over three years and an impressive 905.70% rise over five years. In contrast, the Sensex has shown a 33.63% increase over the same three-year period and 107.98% over five years, highlighting RPG Life Sciences' superior performance relative to the broader market. In terms of profitability, the company boasts a return on capital employed (ROCE) of 49.08% and a return on equity (ROE) of 22.86%, underscoring its effective management and opera...

Read More

RPG Life Sciences Shows Mixed Technical Trends Amid Strong Long-Term Performance

2025-03-07 08:01:46

RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 2,173.80, showing a notable increase from the previous close of 2,118.95. Over the past year, RPG Life Sciences has demonstrated a strong performance, with a return of 43.42%, significantly outpacing the Sensex, which recorded a mere 0.34% return in the same period. The technical summary indicates a mixed outlook, with various indicators reflecting different trends. The MACD shows a mildly bearish stance on a weekly basis but is bullish on a monthly scale. Similarly, the Bollinger Bands and KST present a mildly bearish trend weekly, while the monthly perspective appears more favorable. The daily moving averages suggest a mildly bullish sentiment, indicating some positive momentum in the short term. In terms of ...

Read More

RPG Life Sciences Opens Strong with 5.17% Gain, Outpacing Sector Trends

2025-03-06 09:40:17

RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has shown significant activity today, opening with a gain of 5.17%. The stock's performance has outpaced its sector by 1.38%, marking a notable trend as it has gained for three consecutive days, accumulating a total return of 7.23% during this period. Today, RPG Life Sciences reached an intraday high of Rs 2228.4, reflecting strong market engagement. In terms of moving averages, the stock is currently above its 5-day and 200-day averages, although it remains below the 20-day, 50-day, and 100-day averages. In the broader market context, RPG Life Sciences has performed 1.62% better than the Sensex today, which saw a slight decline of 0.08%. However, over the past month, the stock has faced challenges, declining by 14.82%, compared to the Sensex's drop of 5.62%. Technical indicators suggest a mixed outlook, with the MACD and B...

Read More

RPG Life Sciences Shows Strong Long-Term Returns Amid Mixed Technical Indicators

2025-03-05 08:01:13

RPG Life Sciences, a small-cap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock, which closed at 2088.10, has shown a notable performance over various time frames, particularly in the long term. Over the past year, RPG Life Sciences has delivered a return of 36.64%, significantly outperforming the Sensex, which recorded a mere 1.19% return in the same period. In the three-year and five-year spans, the company has demonstrated remarkable growth, with returns of 320.18% and 805.11%, respectively, compared to the Sensex's 34.34% and 90.03%. This long-term performance highlights the company's resilience and ability to navigate market challenges effectively. However, recent technical indicators present a mixed picture. The MACD and KST metrics indicate a mildly bearish sentiment on both weekly and monthly bases, whi...

Read More

RPG Life Sciences Adjusts Valuation Grade Amid Strong Operational Performance Metrics

2025-03-01 08:00:24

RPG Life Sciences has recently undergone a valuation adjustment, reflecting its current standing in the pharmaceuticals and drugs sector. The company's price-to-earnings ratio stands at 39.82, while its price-to-book value is noted at 9.10. Other key metrics include an EV to EBIT ratio of 24.77 and an EV to EBITDA ratio of 21.48, indicating a robust operational performance. The company has demonstrated a strong return on capital employed (ROCE) of 49.08% and a return on equity (ROE) of 22.86%, showcasing effective management and profitability. Despite a recent decline in stock price, RPG Life Sciences has outperformed the Sensex over longer periods, with a remarkable 321.81% return over three years and a staggering 764.93% over five years. In comparison to its peers, RPG Life Sciences maintains a competitive position, with its valuation metrics aligning closely with other companies in the sector. Notably,...

Read More

View All News